The dual c-Met/VEGFR2 inhibitor foretinib augments chemotherapy response in preclinical models of gastric cancer

被引：1
|
作者：
Awasthi, Niranjan [1 ]
Grojean, Meghan [1 ]
Monahan, Sheena [1 ]
Hassan, Sazzad [1 ]
von Holzen, Urs [1 ]
Schwarz, Margaret A. [1 ]
Schwarz, Roderich E. [1 ]
机构：
[1] Indiana Univ Sch Med, South Bend, IN USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-5807
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5807
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
    Grojean, Meghan
    Schwarz, Margaret A.
    Schwarz, Johann R.
    Hassan, Sazzad
    Holzen, Urs von
    Zhang, Changhua
    Schwarz, Roderich E.
    Awasthi, Niranjan
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (11) : 4950 - 4961
  • [2] The c-Met/VEGFR2 inhibitor XL880 inhibits ovarian cancer cell growth
    Zillhardt, M.
    Sawada, K.
    Jagadeeswaran, S.
    Temkin, S.
    Yamada, D.
    Buller, R.
    Lengyel, E.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S132 - S133
  • [3] Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
    Choueiri, Toni K.
    Vaishampayan, Ulka
    Rosenberg, Jonathan E.
    Logan, Theodore F.
    Harzstark, Andrea L.
    Bukowski, Ronald M.
    Rini, Brian I.
    Srinivas, Sandy
    Stein, Mark N.
    Adams, Laurel M.
    Ottesen, Lone H.
    Laubscher, Kevin H.
    Sherman, Laurie
    McDermott, David F.
    Haas, Naomi B.
    Flaherty, Keith T.
    Ross, Robert
    Eisenberg, Peter
    Meltzer, Paul S.
    Merino, Maria J.
    Bottaro, Donald P.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 181 - 186
  • [4] The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
    Carvalho, Bruno
    Lopes, Jose Manuel
    Silva, Roberto
    Peixoto, Joana
    Leitao, Dina
    Soares, Paula
    Fernandes, Ana Catarina
    Linhares, Paulo
    Vaz, Rui
    Lima, Jorge
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
    Bruno Carvalho
    José Manuel Lopes
    Roberto Silva
    Joana Peixoto
    Dina Leitão
    Paula Soares
    Ana Catarina Fernandes
    Paulo Linhares
    Rui Vaz
    Jorge Lima
    Scientific Reports, 11
  • [6] Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis
    Lee, Changki
    Whang, Young Mi
    Campbell, Preston
    Mulcrone, Patrick L.
    Elefteriou, Florent
    Cho, Sun Wook
    Park, Serk In
    CANCER LETTERS, 2018, 414 : 205 - 213
  • [7] DUAL MET/VEGFR-2 INHIBITOR FORETINIB OVERCOMES ACQUIRED RESISTANCE TO BEVACIZUMAB IN LUNG CANCER
    Xie, Mian
    He, Chao-Sheng
    Wei, Shen-Hai
    Zhang, Li
    RESPIROLOGY, 2013, 18 : 46 - 46
  • [8] Targeting c-Met and VEGFR2 in the stromal compartment of prostate cancer bone metastasis
    Lee, Changki
    Campbell, Preston
    Whang, Young Mi
    Young, Jamey D.
    Elefteriou, Florent
    Park, Serk In
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Visual Function Effects of Foretinib, a Dual MET/VEGFR2 Inhibitor, in a Phase 2 Study for Treatment of Papillary Renal Cell Carcinoma
    Meyerle, Catherine
    Srinivasan, Ramaprasad
    Linehan, W. Marston
    Yeh, Steven
    Chew, Emily
    Chan, Chi-Chao
    Forooghian, Farzin
    Ferris, Frederick
    Zein, Wadih
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [10] Enhancing nab-paclitaxel chemotherapy response in gastric cancer preclinical models through Inhibition of the HGF/c-Met pathway with merestinib
    Kaurich, Quinn
    Huang, Jennifer
    Hassan, Sazzad
    von Holzen, Urs
    Awasthi, Niranjan
    CANCER RESEARCH, 2024, 84 (06)
12345